Implementing a Tribally-Engaged Lung Cancer Screening Program in Rural Oklahoma

Zsolt Nagykaldi, PhD; Mark Doescher, MD; Dorothy Rhoades, MD, MPH; Kathleen Dwyer, PhD, RN; Ann Chou, PhD, MPH; Brook McCann, RN; Natassia Zink, RN

> In partnership with the Choctaw Nation of Oklahoma





DISCLOSURES

- Consultant for: None
- Speaker's Bureau for: None
- Grant/Research support from: NCI R01CA225439
- Stockholder in: None
- Honoraria from: None
- Employee of: University of Oklahoma HSC

I will not discuss off label use and/or investigational use in my presentation. Views expressed are my own and do not necessarily reflect those of my institution, the Choctaw Nation of Oklahoma or the funding agency.

*

TEALS: Background & Aims

Lung cancer screening (LCS) with low-dose computed tomography is a grade-B USPSTF recommendation and reduces mortality by 20%. Implementation of LCS has rarely been studied in American Indian and Alaska Native (AI/AN) communities, many of which are at increased risk of lung cancer.

We initiated the Tribally Engaged Approaches to Lung Screening (TEALS) study in 2019 to co-design and test a tribal community-engaged LCS implementation program:

- <u>Aim 1</u>: Identify individual, community, cultural, health system <u>barriers & facilitators</u> that affect LCS implementation in the Choctaw Nation;
- Aim 2: Use community-engagement processes to co-design a tailored TEALS intervention, which features LCS care coordinators embedded within the CNHSA healthcare delivery system;
- Aim 3: Measure the impact of the LCS program in a clinical trial, assessing process outcomes at the individual and care delivery system level;
- process outcomes at the individual and care delivery system level

* <u>Aim 4</u>: Disseminate the LCS program to other health systems.

*

TEALS: Community Partnership

- TEALS is based on a Community-Engaged Research (CEnR) approach supported by an academic-tribal research subcontract
- TEALS engages 8 primary care centers of the Choctaw Nation Health Services Authority (CNHSA) in Southeast Oklahoma (including 2 LDCT scanner sites) * University of Oklahoma Health Sciences Center and the Stephenson Cancer

	ion
Heads Ser PHealth Stephenon Cancer Center Phone Internet of the Internet of	vices
*	4

TEALS: Study Design & Population

Year 1:	Planning and program co-development with our partners using community-engaged research
Year 2:	Pilot implementation study in 2 CNHSA primary care centers
Years 3-4:	Pair-matched, cluster RCT in 6 CNHSA primary care centers
Year 5:	Dissemination of results and facilitating implementations

- Enrollment: Patients seen in selected practices (N=580), who meet LCS criteria and clinicians/staff/leadership (N~50) from clinic sites
- Quality improvement and implementation facilitation support for LCS: across all CNHSA clinic sites

TEALS: Year-2 Pilot Study

- Two mid-size primary care practice centers were selected to serve as implementation pilot sites (N=100 patients)
- The LCS intervention was based on health systemwide lung cancer screening coordinators (LCCs) both at the local practice centers and centrally, at the health system level



ᆋ

TEALS: Year-2 Pilot Measures

Measures & Timing	Description of Measures	Data Sources and Collection Methods	N (sample)			
Patient measures at	Patient demographics and socio- economic status (SES)	Practice records and short SES survey	50/practice			
baseline and at 6	Patient attitudes toward LCS	Attitudes survey	IN=100			
months	Patient experience with preventive care	CAHPS PCC-10 survey	N=57 (actual)			
Patient measures at 12 months	Patient interviews on experience and satisfaction with the LCS program	Interviews with LCS completers and non- completers	10 per practice 20 total			
Practice measures at baseline and 12 mos	Practice readiness for improvement	CPCQ survey	3 per practice 6 total			
<u>System</u> measures at 12 months	System-level experience with LCS program, decision making factors, feedback	Interviews with CNHSA leadership	10 total			

TEALS: Year-2 Pilot Baseline (1)

Der

- Most patients agreed that their doctors almost always or always explain things in a way that was easy to understand (mean of Likert scale=5.42 [1-6])
- Most patients agreed that their doctors almost always or always spend enough time with them (mean of Likert scale=5.39 [1-6])
- 58% heard about a "lung scan" to find lung cancer before symptoms appear
- 65% agreed that they may get lung cancer during their lifetime, but that "lung scans" will aid early detection and reduce risk

*

Sex (Female):	28	49
Race :	N	%
Native American/American Indian (NA/AI)	44	77
Biracial (White and NA/AI)	12	21
Biracial (African American and NA/AI)	1	0.2
Annual Household Income:	N	%
<\$25,000	30	52
\$25,000-\$50,000	14	25
\$50,000+	6	11
Education:	N	%
High school or less	35	63
At least some college	21	37
 70% reported smoking cigarettes 		
Mean number of cigarettes/day: 23.2		

TEALS: Year-2 Pilot Baseline (2)

Access to Care Characteristics	Mean	Range
Number of visits in 6 months:	4.56	1-7
Preventive Care Patterns:	N	%
Made an appointment for a health checkup with doctor	34	60
Up-to-date on the Following Tests/Exams:	N	%
Mammogram	10	18
Colonoscopy, sigmoidoscopy or stool test	17	30
CT scan to look for lung cancer	22	39

ᆋ

3

TEALS: Year-2 Pilot Patient Surveys (Pre-Post)



TEALS: Year-2 Pilot Qualitative Data

Semi-structured patient interviews (N=15) with screening completers and non-completers: **Contextual Factors in the Clinical Environment**

- Primary care clinician needs to bring up LDCT screening (most frequently noted)
- Use of tailored decision-support materials during clinic visits, e.g., handouts and pamphlets **Barriers to Screening**

- Long distance travel to LCS sites
 Congortunity cost, e.g., missing work (patient or family member driving)
 Gaps in transportation or access to transportation assistance (a major barrier)
 Confusion about the nature of the appointment leading to missed appointments (education!) Characteristics that Influence Individual Decision-Making

11

- Personal motivation to 'be there' for family/children (survival)
 Family history of previous cancers (bad experiences)
- Ease of scheduling appointments
 Some non-completers preferred not to know or were scared to know the results of screening
- *

TEALS: Ongoing RCT Timeline & Design

Task/Time	IAN	168	MAR	APR	MAY	10.01	A.A.	AUG	MP	OCT	NOV	DEC	IAN	110	MAR	APR	MAY	JUN	A.A.	AUK	SIF	OCT	NOV	DEC	Jan	Tub
Patient Recruitment in Group 1	8.																									
					1.																	1				
Practice Oi Interventions in Group 1		1																								
Follow-up Surveys in Group 1					100				1000			1		1												
Patient Recruitment in Group 2		1		*	×				*							-										
						1.0							_			-		-	-	-	-		-		_	_
Practice Qi Interventions In Group 2																8				-					_	-
Follow-up Surveys in Geoup 2																1.0	1.1				1.	1				
Pilot Study Patient Follow-up		×																								
RECRUITMENT G PATIENT SURVEY GOALS:	OA	LS:	240 240 mc	10 LDCT screening-eligible patients in each of the 6 study practices will be consented and recruited into TEALS (N=240) 240 study patients will be surveyed at baseline and re-surveyed within 12 months after their baseline survey (in 2 groups)																						
PATIENT RECORI TRACKING GOAL) .S:		In a of a	addition to recruited (consented) patients we will extract the medical records f another 240 for only tracking of LDCT services received (N=480)																						
PRACTICE INTERVENTION COMPONENTS:			lm "tri scr	Improving smoking status documentation; Implementing screening initiation "triggers" and processes; Implementing shared decision-making for LDCT screening; Patient //u; Smoking cessation services																						
*																									1	12



TEALS Program Implementation Components

- * Large banners offering LDCT screening in participating clinics
- 1.5 FTE lung cancer screening coordinators
 Tribally-tailored education/SDM support materials
- ÷ Academic detailing in all primary care practices
- Practice facilitation in all primary care practices
- Screening registry and data management support
 Smoking cessation service improvements
- Some transportation support (e.g., tribal vehicles)
- ÷ Systematic appointment reminders
- Eligibility triage tool (on iPads)
 Community advisory board
 - Scientific advisory board
- ÷ Clinician "best practices" Clinician champion/advocate



*

÷

TEALS: Lessons Learned So Far

- Due to the nature of primary care, the COVID-19 pandemic deeply impacted community-based prevention programs on many levels (e.g., competing priorities/time; infrastructure; new services/telehealth; economics; backlog of care)
- Primary care-based research must be more flexible, even after the pandemic (e.g., protocols, timelines, measures)
- Rate-limiting LCS steps include: identifying eligible patients (detailed smoking status and reminder algorithms); implementing LCS shared decision-making; providing post-LCS navigation (all of these require extra time and staff)

*

More Lessons: Optimized LCS Process

- * Step 1: Improving smoking status assessment and documentation (frequency and depth)
- Step 2: Implementing screening conversation triggers (regular care and population health)
- Step 3: Instituting an LCS shared decision-making process (in-clinic or post-visit call with an RN/LPN/NP)
- Step 4: Building a preventive <u>care coordination</u> function (coordinator/navigator and screening registry)
- Step 5: Deploying a robust follow-up process
- * Step 6: Linking LCS to smoking cessation

*

TEALS: Next Steps

Complete Data Mining from Pilot Study

- Complete TEALS pilot study data analyses
 Disseminate findings from the pilot study
- Complete the TEALS RCT (final year)
 - Wrap up all interventions in both study groups (N=480 patients)
 - · Collect all post-intervention data at the practice and patient level · Compare two study groups and analyze RCT results
- * Disseminate RCT Results

 - Aggregate all data and learning across all study years
 Create study products, including an Implementation Toolkit
 Disseminate study products to partners (community/scientific)
- *

TEALS: Acknowledgements



Health Stephenson Cancer Center



TEALS is supported by a National Cancer Institute grant (5R01CA225439). The authors have no conflicts of interest.

We thank the Choctaw Nation Health Services Authority Community Advisory Board for their excellent support!

17

*

Questions? Comments?

